Protagonist Therapeutics, Inc. – NASDAQ:PTGX

Protagonist Therapeutics stock price today

$56.2
+17.24
+44.25%
Financial Health
0
1
2
3
4
5
6
7
8
9

Protagonist Therapeutics stock price monthly change

+7.86%
month

Protagonist Therapeutics stock price quarterly change

+7.86%
quarter

Protagonist Therapeutics stock price yearly change

+66.21%
year

Protagonist Therapeutics key metrics

Market Cap
2.40B
Enterprise value
777.34M
P/E
-8.73
EV/Sales
29.24
EV/EBITDA
-4.21
Price/Sales
33.83
Price/Book
4.17
PEG ratio
-2.15
EPS
2.6
Revenue
N/A
EBITDA
151.15M
Income
162.11M
Revenue Q/Q
N/A
Revenue Y/Y
36565.07%
Profit margin
-712.39%
Oper. margin
-729.57%
Gross margin
3.23%
EBIT margin
-729.57%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Protagonist Therapeutics stock price history

Protagonist Therapeutics stock forecast

Protagonist Therapeutics financial statements

Average Price Target
Last Year

$57.33

Potential upside: 2.01%

Based on estimate of 3 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Profit margin
Jun 2023 0 -38.46M
Sep 2023 0 -34.10M
Dec 2023 60M 27.33M 45.56%
Mar 2024 254.95M 207.34M 81.32%
Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Debt to assets
Jun 2023 320466000 26.39M 8.24%
Sep 2023 330016000 27.86M 8.44%
Dec 2023 357951000 21.27M 5.94%
Mar 2024 629276000 68.83M 10.94%
Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Cash Flow
Jun 2023 -26.23M 25.76M 108.17M
Sep 2023 -26.61M -13.55M 35.31M
Dec 2023 16.96M -61.28M 527K
Mar 2024 -27.42M 6.07M 7.19M

Protagonist Therapeutics alternative data

Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Employee count
Aug 2023 103
Sep 2023 106
Oct 2023 106
Nov 2023 106
Dec 2023 111
Jan 2024 111
Feb 2024 111
Mar 2024 112
Apr 2024 112
May 2024 112
Jun 2024 124
Jul 2024 124

Protagonist Therapeutics other data

100.00% 0.00%
of PTGX is owned by hedge funds
50.64M +1.20M
shares is hold by hedge funds

Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Insider trades (number of shares)
Period Buy Sel
Dec 2023 0 75000
Jan 2024 0 5000
Feb 2024 0 9939
Mar 2024 0 57223
Apr 2024 0 26234
Jun 2024 0 43000
Jul 2024 0 8000
Sep 2024 0 22203
Nov 2024 0 256063
Transaction Date Insider Security Shares Price per share Total value Source
Option
MOLINA ARTURO MD officer: Chief Medical Officer
Stock Option (right to buy) 10,000 $8.04 $80,400
Option
MOLINA ARTURO MD officer: Chief Medical Officer
Stock Option (right to buy) 16,000 $8.04 $128,640
Option
MOLINA ARTURO MD officer: Chief Medical Officer
Common Stock 16,000 $8.04 $128,640
Option
MOLINA ARTURO MD officer: Chief Medical Officer
Common Stock 10,000 $8.04 $80,400
Sale
MOLINA ARTURO MD officer: Chief Medical Officer
Common Stock 26,000 $44.67 $1,161,290
Option
MOLINA ARTURO MD officer: Chief Medical Officer
Stock Option (right to buy) 5,529 $8.04 $44,453
Option
MOLINA ARTURO MD officer: Chief Medical Officer
Common Stock 5,529 $8.04 $44,453
Sale
MOLINA ARTURO MD officer: Chief Medical Officer
Common Stock 5,529 $45.6 $252,122
Option
GUPTA SUNEEL officer: Chief De.. Common Stock 30,000 $12.17 $365,100
Option
GUPTA SUNEEL officer: Chief De.. Common Stock 450 $12.17 $5,477
Patent
Application
Filling date: 13 Dec 2021 Issue date: 11 Aug 2022
Application
Filling date: 27 Mar 2020 Issue date: 16 Jun 2022
Application
Filling date: 19 Nov 2021 Issue date: 9 Jun 2022
Application
Filling date: 7 May 2021 Issue date: 10 Feb 2022
Application
Filling date: 29 Dec 2020 Issue date: 2 Dec 2021
Application
Filling date: 28 Jan 2021 Issue date: 25 Nov 2021
Application
Filling date: 14 Jan 2021 Issue date: 26 Aug 2021
Grant
Filling date: 24 Aug 2020 Issue date: 22 Jun 2021
Application
Filling date: 1 Oct 2020 Issue date: 20 May 2021
Grant
Filling date: 12 Dec 2018 Issue date: 9 Mar 2021
Thursday, 19 December 2024
accesswire.com
Friday, 22 November 2024
accesswire.com
Tuesday, 19 November 2024
accesswire.com
Wednesday, 13 November 2024
zacks.com
Thursday, 7 November 2024
zacks.com
accesswire.com
Tuesday, 5 November 2024
accesswire.com
Tuesday, 15 October 2024
zacks.com
Tuesday, 10 September 2024
benzinga.com
Tuesday, 3 September 2024
accesswire.com
Tuesday, 6 August 2024
zacks.com
accesswire.com
Wednesday, 31 July 2024
accesswire.com
Monday, 22 July 2024
accesswire.com
Thursday, 18 July 2024
zacks.com
Thursday, 11 July 2024
investorplace.com
Wednesday, 5 June 2024
investorplace.com
Friday, 31 May 2024
accesswire.com
Tuesday, 14 May 2024
accesswire.com
Tuesday, 7 May 2024
accesswire.com
accesswire.com
Friday, 5 April 2024
Zacks Investment Research
Monday, 18 March 2024
Zacks Investment Research
Friday, 15 March 2024
Zacks Investment Research
Wednesday, 6 March 2024
Accesswire
Monday, 4 March 2024
Zacks Investment Research
Friday, 1 March 2024
Zacks Investment Research
Zacks Investment Research
Zacks Investment Research
Zacks Investment Research
  • What's the price of Protagonist Therapeutics stock today?

    One share of Protagonist Therapeutics stock can currently be purchased for approximately $56.2.

  • When is Protagonist Therapeutics's next earnings date?

    Unfortunately, Protagonist Therapeutics's (PTGX) next earnings date is currently unknown.

  • Does Protagonist Therapeutics pay dividends?

    No, Protagonist Therapeutics does not pay dividends.

  • How much money does Protagonist Therapeutics make?

    Protagonist Therapeutics has a market capitalization of 2.40B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 125.73% to 60M US dollars.

  • What is Protagonist Therapeutics's stock symbol?

    Protagonist Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "PTGX".

  • What is Protagonist Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Protagonist Therapeutics?

    Shares of Protagonist Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Protagonist Therapeutics's key executives?

    Protagonist Therapeutics's management team includes the following people:

    • Dr. Dinesh V. Patel Ph.D. Chief Executive Officer, Pres, Interim PAO, Sec. & Director(age: 68, pay: $1,040,000)
    • Dr. David Y. Liu Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel.(age: 75, pay: $719,420)
    • Dr. Suneel K. Gupta Ph.D. Chief Devel. Officer(age: 67, pay: $680,320)
  • How many employees does Protagonist Therapeutics have?

    As Jul 2024, Protagonist Therapeutics employs 124 workers, which is 11% more then previous quarter.

  • When Protagonist Therapeutics went public?

    Protagonist Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 11 Aug 2016.

  • What is Protagonist Therapeutics's official website?

    The official website for Protagonist Therapeutics is protagonist-inc.com.

  • Where are Protagonist Therapeutics's headquarters?

    Protagonist Therapeutics is headquartered at 7707 Gateway Boulevard, Newark, CA.

  • How can i contact Protagonist Therapeutics?

    Protagonist Therapeutics's mailing address is 7707 Gateway Boulevard, Newark, CA and company can be reached via phone at +51 04740170.

  • What is Protagonist Therapeutics stock forecast & price target?

    Based on 3 Wall Street analysts` predicted price targets for Protagonist Therapeutics in the last 12 months, the avarage price target is $57.33. The average price target represents a 2.01% change from the last price of $56.2.

Protagonist Therapeutics company profile:

Protagonist Therapeutics, Inc.

protagonist-inc.com
Exchange:

NASDAQ

Full time employees:

126

Industry:

Biotechnology

Sector:

Healthcare

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

7707 Gateway Boulevard
Newark, CA 94560-1160

CIK: 0001377121
ISIN: US74366E1029
CUSIP: 74366E102